Progressive clinical effects of the combination omalizumab and HDM - allergen immunotherapy in asthma

CONCLUSION: The combination of HDM SCIT and omalizumab is significantly and progressively reducing ICS use and AX in a 24-month study. The combination is significantly more effective than the single treatments or placebo.PMID:38064236 | DOI:10.1080/02770903.2023.2293057

Source: Journal of Asthma - December 8, 2023 Category: Respiratory Medicine Authors: Andrzej Bozek Barbara Rogala Martyna Miodonska Giorgio Walter Canonica Source Type: research